At the time of writing, Viridian Therapeutics Inc [VRDN] stock is trading at $19.27, up 2.66%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRDN shares have gain 3.66% over the last week, with a monthly amount drifted -2.08%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 16, February 2024, Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer. In a post published today on Yahoo Finance, Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jennifer Tousignant to the role of Chief Legal Officer.
From an analyst’s perspective:
Previously, BTIG Research started tracking the stock with Buy rating on June 14, 2023, and set its price target to $46. On May 30, 2023, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $44 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $46 on April 17, 2023. Stifel initiated its recommendation with a Buy and recommended $49 as its price target on March 30, 2023. Needham started tracking with a Buy rating for this stock on December 19, 2022, and assigned it a price target of $45. In a note dated December 19, 2022, Cowen initiated an Outperform rating and provided a target price of $45 on this stock.
For the past year, the stock price of Viridian Therapeutics Inc fluctuated between $10.93 and $34.70. Currently, Wall Street analysts expect the stock to reach $44.4 within the next 12 months. Viridian Therapeutics Inc [NASDAQ: VRDN] shares were valued at $19.27 at the most recent close of the market. An investor can expect a potential return of 130.41% based on the average VRDN price forecast.
Analyzing the VRDN fundamentals
According to Viridian Therapeutics Inc [NASDAQ:VRDN], the company’s sales were 0.35M for trailing twelve months, which represents an -93.97% plunge. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.60 points at the first support level, and at 17.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.84, and for the 2nd resistance point, it is at 20.42.
Viridian Therapeutics Inc [VRDN] reported earnings per share of -$1.09 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.27/share, meaning a difference of $0.18 and a surprise factor of 14.20%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$1.27 per share as compared to estimates of -$1.29 per share, a difference of $0.02 representing a surprise of 1.60%.
Ratios To Look Out For
It is important to note that Viridian Therapeutics Inc [NASDAQ:VRDN] has a current ratio of 13.93. On the other hand, the Quick Ratio is 13.93, and the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 2895.46, the price to book ratio is 5.66.
Transactions by insiders
Recent insider trading involved Fairmount Funds Management LLC, Director, that happened on Jan 22 when 0.48 million shares were purchased. Chief Legal Officer, Meisner Lara completed a deal on Jun 16 to sell 27.0 shares. Meanwhile, Chief Legal Officer Meisner Lara sold 2269.0 shares on Jun 15.
